Apyx Medical Corporation
NASDAQ:APYXMedical - Devices
-$0.08 today
- Market cap
- $104.89M
- Beta
- 1.39
- P/E (TTM)
- -19.0
- EPS (TTM)
- -$0.22
Volume 0.19M
Average 0.18M
APYX Total Current Assets
All assets expected to be converted to cash or used up within one year.
Apyx Medical CorporationNASDAQ: APYX
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 5.7% from a year ago
Total current assets stood at $54.8M at the end of Q1 FY2026, up 5.7% from a year earlier and down 6.3% from the prior quarter. Over 3 fiscal years it compounded at +10.8% a year.
Context
- Total current assets amounted to 86.9% of total assets at the end of Q1 FY2026, up 0.8 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +5.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 58.47M USD
- Year-over-year change
- +3.6%
- 4-year CAGR
- -0.9%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 58.47M | +3.6% |
| FY2024 | 2024-12-31 | 56.44M | -19.8% |
| FY2023 | 2023-12-31 | 70.36M | +63.7% |
| FY2022 | 2022-12-31 | 42.97M | -29.2% |
| FY2021 | 2021-12-31 | 60.74M | — |
Total Current Assets vs competitors
How APYX compares with its peers on the latest reported figures
- APYX's Mar 2026 total current assets of $54.8M is the 2nd highest of the 8 companies compared; the peer median is $49.23M.
- Its year-over-year change of +5.7% is the 4th highest of 8, against a peer median of +5.2%.
- Total current assets amounts to 86.9% of total assets for APYX, versus a peer median of 71.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $62.62M | -9.4% | +16.6% | 80.3% | |
| Mar 2026 | $54.8M | +5.7% | +10.8% | 86.9% | |
| Mar 2026 | $53.71M | +7.5% | +14.9% | 71.6% | |
| Mar 2026 | $49.73M | +5.2% | -23.2% | 53.2% | |
| Mar 2026 | $49.23M | -28.8% | -23.9% | 78.9% | |
| Mar 2026 | $31.65M | -34.0% | -26.0% | 61.4% | |
| Mar 2026 | $31.36M | +13.9% | +15.4% | 92.0% | |
| Mar 2026 | $21.55M | +45.1% | -27.8% | 50.9% | |
| Peer median (excluding APYX) | $49.23M | +5.2% | -23.2% | 71.6% | |
Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30.87M | 10.19M | 43.65M | 31.74M | 31.74M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 21.16M | 18.25M | 14.02M | 15.48M | 16.78M |
| Inventory | 6.78M | 11.8M | 9.92M | 7.56M | 8.6M |
| Other Current Assets | 0 | 2.74M | 2.76M | 1.66M | 1.35M |
| Total Current Assets | 60.74M | 42.97M | 70.36M | 56.44M | 58.47M |
| Property, Plant & Equipment (Net) | 6.87M | 7.59M | 7.15M | 6.74M | 6.62M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.11M | 1.22M | 1.73M | 1.66M | 1.75M |
| Total Non-current Assets | 7.98M | 8.8M | 8.88M | 8.4M | 8.37M |
| Total Assets | 68.72M | 51.78M | 79.24M | 64.84M | 66.84M |
| Account Payables | 2.63M | 2.67M | 2.71M | 2.62M | 3.06M |
| Short-term Debt | 0 | 0 | 0 | 355K | 428K |
| Tax Payables | 2.29M | 2.08M | 0 | 0 | 0 |
| Deferred Revenue | 533K | 853K | 488K | 693K | 0 |
| Other Current Liabilities | 2.12M | 0 | 1.55M | 5.08M | 8.21M |
| Total Current Liabilities | 13.21M | 11.85M | 12.74M | 10.72M | 11.7M |
| Long-term Debt | 0 | 0 | 33.19M | 33.89M | 34.85M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.32M | 1.41M | 1.25M | 1.12M | 1.05M |
| Other Non-current Liabilities | 166K | 181K | 198K | 259K | 347K |
| Total Non-current Liabilities | 1.51M | 2.13M | 39.58M | 39.79M | 40.31M |
| Total Liabilities | 14.71M | 13.98M | 52.32M | 50.51M | 52.01M |
| Common Stock | 34K | 35K | 35K | 38K | 42K |
| Retained Earnings | (12.55M) | (35.74M) | (54.45M) | (77.91M) | (89.12M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 305K | 211K | 221K | 125K | 291K |
| Total Equity | 54.01M | 37.79M | 26.92M | 14.34M | 14.83M |
| Total Debt | 305K | 796K | 38.5M | 38.76M | 39.34M |
| Net Debt | (30.57M) | (9.4M) | (5.15M) | 7.02M | 7.6M |
Apyx Medical Corporation
NASDAQ:APYX
Intrinsic Alpha fair value
Locked
Current Price
$2.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.